Rapport Therapeutics (RAPP) Total Current Liabilities (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Total Current Liabilities for 4 consecutive years, with $17.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 90.74% year-over-year to $17.9 million; the TTM figure through Mar 2026 stood at $17.9 million (up 90.74% YoY), while the FY2025 annual figure was $19.0 million, up 117.28% from the prior year.
• Total Current Liabilities declined to $17.9 million in Q1 2026 per RAPP's latest filing, from $19.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $19.0 million in Q4 2025 and bottomed at $7.1 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $11.7 million across 4 years, with a median of $9.4 million in 2025.
• Annual changes were most pronounced in 2024 — Total Current Liabilities decreased 0.41% — and 2025, when it surged 117.28%.
• Rapport Therapeutics' Total Current Liabilities stood at $8.8 million in 2023, then decreased by 0.41% to $8.8 million in 2024, then soared by 117.28% to $19.0 million in 2025, then slipped by 6.05% to $17.9 million in 2026.
• Business Quant data shows RAPP's Total Current Liabilities at $17.9 million in Q1 2026, $19.0 million in Q4 2025, and $14.3 million in Q3 2025.